PVLA vs SGMT: fair value comparison
Palvella Therapeutics, Inc. and Sagimet Biosciences Inc. · Updated 2026-10-19
PVLA has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. SGMT has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, PVLA currently ranks higher by quality score.
| PVLA | SGMT | |
|---|---|---|
| Verdict | No estimate yet | No estimate yet |
| Last price | $120.30 | $8.02 |
| 12-month range | $70.43–$158.13 | $4.55–$11.17 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #262 of 301 Healthcare | #263 of 301 Healthcare |
| Quality grade | F | F |
| Leverage | Low | Low |
| Margin trend | Expanding | — |
| Revenue growth | Declining | Declining |
| RSI zone | Oversold | Neutral |
| 50/200-day trend | Mixed | Mixed |
| 52-week position | The upper-middle quarter | The upper-middle quarter |
Full single-stock breakdowns: PVLA fair value analysis · SGMT fair value analysis